VC-backed Juno Therapeutics taps mutual funds in $134 mln funding


Juno Therapeutics, a Seattle-based biotech company focused on developing immunotherapies for cancer, has raised $134 million in Series B funding. The investors in this round were not named; however, the firm says that “10 public mutual funds and healthcare-focused funds” participated in the round.

According to the company, Juno has raised more than $300 million. This past April, the company closed $176 million on its Series A round. Investors were Bezos Expeditions, the personal investment arm of CEO Jeff Bezos, and Venrock.

Founded by Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center and Seattle Children’s Research Institute, Juno Therapeutics launched in December 2013 with $120 million. Its initial backers included ARCH Venture Partners and the Alaska Permanent Fund through a partnership managed by Crestline Investors.

Leerink Partners advised Juno on this transaction.

Photo courtesy of Shutterstock. 

Leave a Reply

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget